Healthpeak Properties, Inc.
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Scott M. Brinker
- Full Time Employees
- 193
- Sector
- Real Estate
- Industry
- REIT - Healthcare Facilities
- Address
- 5050 South Syracuse Street Denver CO United States of America 80237
- IPO Date
- May 23, 1985
- CIK
- 0000765880
- Website
- healthpeak.com
- Similar Companies
- Business
- Healthpeak Properties, Inc. Healthpeak Properties, Inc. (NYSE: DOC) is a fully integrated real estate investment trust (REIT) and S&P 500 company that acquires, owns, operates, develops, leases and manages high-quality healthcare real estate focused on healthcare discovery and delivery; its core portfolio segments include lab properties containing laboratory and office space for life science and biotechnology tenants, outpatient medical buildings and hospitals serving healthcare providers and physician groups, and continuing care retirement communities (CCRCs) offering independent living, assisted living, memory care and skilled nursing units. The company maintains a diversified portfolio of approximately 700 properties encompassing nearly 50 million square feet, strategically located in key U.S. growth markets such as San Francisco, San Diego, Boston, Atlanta and Dallas, with major tenants including leading hospital systems, biopharma companies like Pfizer Inc. and Bristol-Myers Squibb Co., independent physician groups and regional health systems. Founded in 1985 and headquartered in Denver, Colorado, with additional offices in Irvine, Nashville and San Francisco, Healthpeak Properties serves healthcare professionals, patients, researchers and seniors nationwide through properties like Torrey Pines Science Park, Medical City Dallas Hospital Campus, The Cove at Oyster Point and Freedom Plaza Sun City Center. In March 2024, the company completed an all-stock merger of equals with Physicians Realty Trust valued at approximately $21 billion, acquiring 299 outpatient medical buildings, changing its NYSE ticker from PEAK to DOC, expanding its board with five new directors from Physicians Realty Trust, and securing a $750 million five-year unsecured term loan at a fixed 4.5% interest rate to fund integration and general corporate purposes; the merger has delivered synergies exceeding initial targets at over $65 million, internalized property management in multiple markets ahead of schedule, and strengthened affiliations with all 10 largest U.S. health systems. Healthpeak continues to execute new leases totaling 1.5 million square feet in recent quarters with high retention rates of 85-88% in outpatient medical and lab spaces, enter development agreements such as $148 million projects with Northside Hospital in Atlanta, announce leadership enhancements including Denis Sullivan as Managing Director of Lab Investments and San Diego Market Lead and Mike Dorris as Head of West Coast Development, and advance sustainability initiatives like an 8.2% reduction in greenhouse gas emissions and new LEED certifications as detailed in its 2024 Corporate Impact Report.
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
PEAK:AIO and Los Alamos National Laboratory Launch Lattice - Breaking Open the Metadata Bottleneck in Parallel File Systems
Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
F45 Training Introduces F45 PEAK500: A New Era of Standardized Athletic Performance Testing
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
Y Intercept Hong Kong Ltd Raises Stock Holdings in Healthpeak Properties, Inc. $DOC
Cullen Frost Bankers Inc. Increases Position in Healthpeak Properties, Inc. $DOC
Chicago Partners Investment Group LLC Invests $205,000 in Healthpeak Properties, Inc. $DOC
Healthpeak Properties, Inc. (DOC) Q3 2025 Earnings Call Transcript
Will Campbell's PEAK Savings Program Lift Margins by 2028?
Healthpeak Properties: Trading Near Decade Lows
Healthpeak Properties, Inc. (DOC) Q1 2025 Earnings Call Transcript
5 Monthly-Paying REITs To Sleep Well At Night
Healthpeak Properties, Inc. (DOC) Q4 2024 Earnings Call Transcript
HealthPeak Boosts Flexibility With $3B Revolving Credit Facility
HMS Networks has completed the acquisition of PEAK-System Technik
Healthpeak Properties, Inc. (DOC) Q3 2024 Earnings Call Transcript
HMS Networks acquires PEAK-System Technik and strengthens its position within Industrial Information and Communication Technology (ICT)